Margaret Ma

Margaret Ma

Auto-generated profile, based on publicly available information

Margaret Ma

Division of Rheumatology and Allergy, Department of Medicine National University Hospital Singapore Singapore

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2020 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
MMM. H. Y. Ma
M. H. Y. Ma
NDN. Defranoux
N. Defranoux
WLW. Li
W. Li
ESE. H. Sasso
E. H. Sasso
FIF. Ibrahim
F. Ibrahim
ACA. P. Cope
A. P. Cope
Background: Reliable assessment of remission is important for the optimal management of rheumatoid arthritis (RA) patients. In this study, we used the multi-biomarker disease activity (MBDA) test to explore the role of biomarkers in predicting point remission and sustained remission.Methods: RA patients on > 6 months stable therapy in stable low disease activity (DAS28-ESR ≤ 3.2) were assessed every 3 months for 1 year. Baseline, intermittent (IR) and sustained (SR) remission were defined by DAS28-ESR, DAS28-CRP, simple disease activity index (SDAI), clinical disease activity index (CDAI) and ACR/EULAR Boolean criteria. Patients not fulfilling any remission criteria at baseline were classified as ‘low disease activity state’ (LDAS). Patients not fulfilling any remission criteria over 1 year were classified as ‘persistent disease activity’ (PDA). MBDA score was measured at baseline/3/6 months. The baseline MBDA score, the 6-month time-integrated MBDA score and MBDA biomarkers were used for analyses. The area under the receiver operating characteristic curve (AUROC) assessed the ability of the MBDA score to discriminate between remission and non-remission. Biomarkers were analysed at baseline using the Mann-Whitney test and over time using the Jonckheere-Terpstra trend test.Results: Of 148 patients, 27% were in the LDAS, 65% DAS28-ESR remission, 51% DAS28-CRP remission, 40% SDAI remission, 43% CDAI remission and 25% ACR/EULAR Boolean remission at baseline. Over 1 year, 9% of patients were classified as PDA. IR and SR were achieved in 42%/47% by DAS28-ESR, 46%/29% by DAS28-CRP, 45%/20% by SDAI, 44%/21% by CDAI and 35%/9% by ACR/EULAR Boolean criteria, respectively. By all remission criteria, baseline MBDA score discriminated baseline remission (AUROCs 0.68–0.75) and IR/SR (AUROCs 0.65–0.74). The 6-month time-integrated MBDA score discriminated IR/SR (AUROCs 0.65–0.79). Baseline MBDA score and concentrations of IL-6, leptin, SAA and CRP were significantly lower in all baseline remission criteria groups vs LDAS. They and the 6-month time-integrated values were lower among patients who achieved IR/SR vs PDA over 1 year.Conclusions: This study demonstrated that the MBDA score and its biomarkers IL-6, leptin, SAA and CRP differentiated between small differences in disease activity (i.e. between low disease activity and remission states). They were also predictors of remission over 1 year.

29 November 2022 in Journal of Autoimmunity
Verified
Journal Article
Open access
MMMargaret Ma
Margaret Ma
ASAmelia Santosa
Amelia Santosa
WFWarren Fong
Warren Fong
LCLi-Ching Chew
Li-Ching Chew
ALAndrea Hl Low
Andrea Hl Low
MLManjari Lahiri
Manjari Lahiri
Studies of flares of autoimmune inflammatory rheumatic diseases (AIIRD) after COVID-19 mRNA vaccination are limited by small sample size, short follow up or at risk of selection bias. A national retrospective cohort study of consecutive AIIRD patients ≥12 years old, across 8 hospitals who received at least one dose of a COVID-19 mRNA vaccine. Patients were included from the date of 1st vaccine dose and censored at the time of flare or on the date of the clinic visit at least 3 months from cohort entry, whichever came first. Predictors of flare were determined by Cox proportional hazards analysis. 4627 patients (73% Chinese, 71% female) of median (IQR) age 61 (48, 70) years were included; 42% Rheumatoid arthritis, 14% Systemic lupus erythematosus and 11% Psoriatic arthritis. 47% were in remission, 41% low disease activity, 10% moderate disease activity and 1% in high disease activity. 18% patients flared, of which 11.7% were within the 3-month period of interest. 11.8% patients improved. Median (IQR) time-to-flare was 60 (30, 114) days. 25% flares were self-limiting, 61% mild-moderate and 14% severe. Older patients (53–65 years and >66 years) had a lower risk of flare [HR 0.6 (95% CI 0.5–0.8) and 0.7 (0.6–0.8) respectively]. Patients with inflammatory arthritis and with active disease had a higher risk of flare [HR 1.5 (1.2–2.0) and 1.4 (1.2–1.6), respectively]. Treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), immunosuppression and prednisolone was also associated with an increased risk of flare [HR 1.5 (1.1–2), 1.2 (1.1–1.4) and 1.5 (1.2–1.8) for prednisolone ≤7.5 mg respectively]. There was a moderately high rate of AIIRD flares after mRNA vaccination but also improvement in several patients. Severe flares and hospitalisation were rare. Thus, vaccination remains safe and highly recommended.

30 October 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
CCCarl Coyle
Carl Coyle
MMMargaret Ma
Margaret Ma
YAYann Abraham
Yann Abraham
CMChristopher B. Mahony
Christopher B. Mahony
KSKathryn Steel
Kathryn Steel
EPEsperanza Perucha
Esperanza Perucha
Rheumatoid arthritis (RA) is an immune-mediated, chronic inflammatory condition. With modern therapeutics and evidence-based management strategies, achieving sustained remission is increasingly common. To prevent complications associated with prolonged use of immunosuppressants, drug tapering or withdrawal is recommended. However, due to the lack of tools that define immunological remission, disease flares are frequent, highlighting the need for a more precision medicine–based approach. Utilizing high-dimensional phenotyping platforms, we set out to define peripheral blood immunological signatures of sustained remission in RA. We identified that CD8 + CD57 + KIR2DL1 + NK cells are associated with sustained remission. Functional studies uncovered an NK cell subset characterized by normal degranulation responses and reduced proinflammatory cytokine expression, which was elevated in sustained remission. Furthermore, flow cytometric analysis of NK cells from synovial fluid combined with interrogation of a publicly available single-cell RNA-Seq dataset of synovial tissue from active RA identified a deficiency of the phenotypic characteristics associated with this NK cell remission signature. In summary, we have uncovered an immune signature of RA remission associated with compositional changes in NK cell phenotype and function that has implications for understanding the effect of sustained remission on host immunity and distinct features that may define operational tolerance in RA.

15 September 2020 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
MMMargaret H.Y. Ma
Margaret H.Y. Ma
Sen Hee TaySen Hee Tay
Sen Hee Tay
PCPeter P.M. Cheung
Peter P.M. Cheung
ASAmelia Santosa
Amelia Santosa
YCYiong Huak Chan
Yiong Huak Chan
MLManjari Lahiri
Manjari Lahiri
Objective.: To evaluate attitudes and behaviors of patients with rheumatic diseases during the coronavirus disease 2019 (COVID-19) pandemic.Methods.: An online survey delivered by text message to 4695 patients on follow-up at a tertiary rheumatology center. Latent class analysis was performed on the survey variables.Results.: There were 2239 (47.7%) who responded to the survey and 3 clusters were identified. Cluster 3 (C3) was defined by patients who were most worried about COVID-19, more likely to wear face masks, and more likely to alter or stop their medications. Patients in C3 were more likely to be female, Malay, and unemployed.Conclusion.: We identified 3 clusters with different healthcare beliefs and distinct sociodemographics.

15 June 2026 in International Journal of Rheumatic Diseases
Verified
Journal Article
Open access
PDPreeti Dhanasekaran
Preeti Dhanasekaran
SYSiaw Ing Yeo
Siaw Ing Yeo
YNYi Xin Ng
Yi Xin Ng
RLRosa Lim
Rosa Lim
SWStephanie Wong
Stephanie Wong
MMMargaret Ma
Margaret Ma
Purpose: To determine the association of body mass index (BMI) with incident COVID‐19 infection in patients with inflammatory arthritis (IA) using biologic disease‐modifying anti‐rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) and to describe characteristics of patients with severe COVID‐19 infection. Methods: This prospective inception cohort study included IA patients ≥ 21 years old initiating a bDMARD after July 2016 across five public hospitals in Singapore. Data were collected via questionnaires and electronic medical records. Baseline characteristics were compared between patients who developed COVID‐19 and those who did not. The association between BMI and time to incident COVID‐19 infection was assessed using Cox proportional hazards regression, adjusting for demographic and clinical factors. Results: Five hundred sixty‐one patients (60.1% female, 69.0% Chinese; median age 49.0 years) were included. Diagnoses included rheumatoid arthritis (39.6%), psoriatic arthritis (26.6%), and spondyloarthritides (33.9%). Most (63.8%) were on tumor necrosis factor (TNF) inhibitors. SARS‐CoV‐2 infection occurred in 140 (25.0%) patients. Those infected had higher BMI (27.0 vs. 25.0 kg/m 2 , p = 0.005). BMI ≥ 23 kg/m 2 was independently associated with increased risk of infection (HR 1.63 [95% CI 1.05, 2.53]; p = 0.029). Severe COVID‐19 infection occurred in five patients. All were male, and four had underlying comorbidities. The underlying rheumatic diagnoses included rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. These patients were receiving b/tsDMARDs including golimumab, tofacitinib, adalimumab biosimilar (Amgevita), and infliximab biosimilar (Remsima). Importantly, no deaths were reported. Conclusion: Being overweight or obese (BMI ≥ 23 kg/m 2 ) was independently associated with higher COVID‐19 infection risk. Severe infections were rare.

25 August 2026 in The American Journal of Medicine
Verified
Journal Article
Closed access
INIsaac Ks Ng
Isaac Ks Ng
JTJiekai Tan
Jiekai Tan
ALAn Jian Leung
An Jian Leung
ELElaine Ag Lo
Elaine Ag Lo
KPKee Fong Phang
Kee Fong Phang
MMMargaret Ma
Margaret Ma